Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
5.50
-0.46 (-7.72%)
At close: Apr 28, 2026, 4:00 PM EDT
5.55
+0.05 (0.85%)
After-hours: Apr 28, 2026, 7:52 PM EDT
Personalis Revenue
In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%. Personalis had revenue of $17.35M in the quarter ending December 31, 2025, with 3.24% growth.
Revenue (ttm)
$69.65M
Revenue Growth
-17.69%
P/S Ratio
8.27
Revenue / Employee
$267,877
Employees
260
Market Cap
575.73M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
PSNL News
- 5 days ago - Personalis to Announce First Quarter 2026 Financial Results - Business Wire
- 7 days ago - Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 - Business Wire
- 15 days ago - Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 - Business Wire
- 27 days ago - Personalis to Participate in the 25th Annual Needham Virtual Conference - Business Wire
- 6 weeks ago - Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption - Business Wire
- 6 weeks ago - Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® - Business Wire
- 2 months ago - Personalis Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - Business Wire